Brandon Scalea

Joaquim Bellmunt, MD, PhD, provides insight on how to navigate the complex treatment paradigm of metastatic bladder cancer.

Matthew S. Davids, MD, MMSc, discusses the clinical implications of the DUO trial in patients with chronic lymphocytic leukemia.

Michael Wang, MD, discusses the promise of single-agent acalabrutinib in the treatment of patients with relapsed/refractory mantle cell lymphoma.

Elaine Shum, MD, discusses the rapidly evolving treatment options for patients with oncogene-driven non–small cell lung cancer.

Chris Parker, MD, discusses the clinical implications of STAMPEDE and how radiotherapy fits into the treatment paradigm for these patients.

Chul Kim, MD, MPH, discusses the additions of EGFR inhibitors to the lung cancer armamentarium and how to best select therapy for these patients.

Pashtoon M. Kasi, MD, MBBS, MS, discusses advances and unmet needs in metastatic colorectal cancer.

Walter Rayford, MD, PhD, MBA, discusses a race-based study in prostate cancer and how these results can drive treatment and diagnostic strategies.

Ryan B. Corcoran, MD, PhD, discusses the clinical utility and benefits of liquid biopsies in gastrointestinal cancers.

The new standard of care for the frontline treatment of patients with extensive-stage small cell lung cancer should be atezolizumab and chemotherapy, based on results from the IMpower133 trial.

Bradley G. Somer, MD, discusses the potential of combination regimens for patients with metastatic renal cell carcinoma.

Adam M. Brufsky, MD, PhD, discusses the impact of biosimilars in the field of oncology and outlined other strategies and steps that can be taken to mitigate cost when treating patients with breast cancer.

Yana Pikman, MD, discusses the clinical implications of using an approach to match targeted therapy to pediatric patients with leukemia.

Kimberly S. Corbin, MD, sheds light on the use of proton radiation therapy in the breast cancer space and which patients may benefit from this approach.

Toni K. Choueiri, MD, discusses recent progress in RCC and where future research is heading in the field.

Tycel J. Phillips, MD, discusses the clinical implications of acalabrutinib plus bendamustine and rituximab for patients with mantle cell lymphoma.

Oscar J. Manrique, MD, discusses the current treatments for patients with lymphedema who have breast cancer and the challenges that remain in this space.

Benjamin L. Maughan, MD, PharmD, discusses the activity of the combination of radium-223 and enzalutamide in patients with metastatic castration-resistant prostate cancer.

Paul R. Eber, MD, discusses how the findings from CARMENA impact metastatic renal cell carcinoma treatment and what challenges remain.

Maurie Markman, MD, discusses the evolution of biosimilars and ongoing efforts to make treatments more affordable for patients with cancer.

C. Ola Landgren, MD, PhD, discusses the role of minimal residual disease negativity and the emergence of CAR T-cell therapy in multiple myeloma.

Adham Jurdi, MD, discusses how the updated data from the PACIFIC trial have changed the standard of care for patients with stage III non–small cell lung cancer.

Scott T. Tagawa, MD, MS, discusses the clinical significance of recent clinical trial data in patients with nonmetastatic prostate cancer.

Although gastric and gastroesophageal junction cancers are heterogeneous diseases with a number of FDA-approved regimens, TAS-102 may have a place in the management of previously treated patients, according to Hendrik-Tobias Arkenau, MD, PhD.

Recent data have moved the needle across the board in oncology, specifically with lung cancer and gastrointestinal cancers, with immunotherapy and targeted agents paving the way for an improvement in survival outcomes.

Cathy Eng, MD, shares her insight on the current paradigm of gastrointestinal cancers, specifically colorectal cancer and hepatocellular carcinoma.

Julie R. Brahmer, MD, discusses updates on the use of immunotherapy in patients with metastatic non–small cell lung cancer.

Pembrolizumab has emerged as a reliable frontline treatment option for patients with metastatic non–small cell lung cancer, but thoracic oncologists need to be aware of potentially severe immune-related adverse events.

Deepa S. Subramaniam, MBBS, MSc, discusses the complex and evolving treatment paradigm of BRAF- and ROS1-driven non–small cell lung cancer.

Ruth O’Regan, MD, discusses the current landscape of hormone receptor–positive breast cancer and the unanswered questions that still need to be addressed.